You are browsing in:
Tag: dogs

Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial

/0 Comments/in , , /by

M. Salichs, L. Badiella, P. Sarasola and J. Homedes | Veterinary Record | September 2021
The aim of this prospective randomised controlled trial was to confirm the safety and efficacy of enflicoxib for the treatment of naturally occurring osteoarthritis (OA) in dogs…

Read more →

Results of urinary bacterial cultures and antibiotic susceptibility testing of dogs and cats in the UK

/0 Comments/in , , /by

J.D. Fonseca, D.E. Mavrides, P.A. Graham and T.D. McHugh | Journal of Small Animal Practice | August 2021
The aim of this retrospective study was to investigate the antibiotic resistance of bacterial uropathogens in dogs and cats in the UK…

Read more →

Using psychopharmacology in the treatment of problem behaviours in dogs and cats

/0 Comments/in , , /by

C. Warnes | UK-Vet Companion Animal | October 2021
This review article, written by a veterinary behaviourist, provides an overview of some of the behaviourally-active drugs that are used to treat dogs and cats in the UK and discusses some of the factors that need to be considered when using medication as part of behaviour modification in cats and dogs…

Read more →

A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine

/0 Comments/in /by

| Journal of the American Veterinary Medical Association | 2021 | The aim of this randomised placebo-controlled, double-blinded trial was to assess the impact of prophylactic administration of omeprazole or famotidine on the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam …

Read more →

A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine

/1 Comment/in , , /by

M.H. Shaevitz, G.E. Moore and C.M. Fulkerson | Journal of the American Veterinary Medical Association | August 2021
The aim of this randomised placebo-controlled, double-blinded trial, which was carried at a Veterinary Teaching Hospital in the United States and funded by the Veterinary Cancer Society’s Resident Research Award, was to assess the impact of prophylactic administration of omeprazole or famotidine on the incidence and severity of gastrointestinal (GI) adverse events (AEs) in dogs with cancer treated with piroxicam…

Read more →

Prediction of clinically important acquired cardiac disease without an echocardiogram in large breed dogs using a combination of clinical, radiographic and electrocardiographic variables

/0 Comments/in , , /by

S. Wesselowski, S.G. Gordon, N. Meddaugh, A.B. Saunders, J. Häggström, K. Cusack, B.W. Janacek and D.J. Matthews | Journal of Veterinary Cardiology | August 2021
The objectives of this retrospective study were to (1) assess the clinical utility of thoracic radiographs and (2) to explore the potential utility of prediction models incorporating radiographic measurements, physical examination (PE) and electrocardiogram (ECG) to predict clinically important dilated cardiomyopathy (DCM) or myxomatous mitral valve disease (MMVD) in the absence of an echocardiogram in large-breed (LB) dogs…

Read more →